The Effect of NAC on Lung Function and CT Mucus Score
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma
that is complicated by mucus in the airway, as determined by CT imaging. The study is a
crossover design, which means that half the study participants will get 20% NAC in the first
14-day treatment period and placebo in the next 14-day treatment period; and the other half
will get placebo in the first 14-day treatment period and 20% NAC in the next 14-day
treatment period.